Obesity management to advance as the second most lucrative drug type segment

Medical - Mohit Shah - May 04,2017

Rating -

stars - based on 21 reviews

obesity management to advance as the second most lucrative drug type segment

According to active statistics, in the upcoming years between 2017 and 2027, the market linked to obesity management is estimated to grow at a CAGR of 4.9%.

Obesity is seen as one of the evilest terrors of our modern day lifestyle. Presently, there are different obesity management solutions which have been existing to curb this issue suffered by the global population.

As per the recent market research report offered by Future Market Insights (FMI), the average growth of the worldwide obesity management sector is estimated to grow from US$ 641.6 Mn in 2016 to US$ 1,078.9 by the end of 2027; it represents a value CAGR of 4.9% during this stated period. These figures are quite impressive considering the various other drug type segments.

Depending on the regional segregation, the obesity management market is primarily dominated by North America’s contribution to global revenues that will exceed 33% by the end of 2027. This region is anticipated to become the largest market for obesity management. Also, Western Europe enjoys a reputed status, with the offering of an estimated US$ 222 Mn in revenues as the year 2027 concludes. 

However, the high costs involved in the research & development (R&D) of obesity drugs, merged with limited financial support, are jointly posing a greater challenge for the adoption of obesity management solutions. Additionally, the inclusion of clinical trials required to test these drugs scrambles the expenditure significantly. With the presence of such risks and limitations modeled by the high development costs of obesity drugs, the growth of the obesity management market on the global platform is bound to get obstructed.

The scares aren’t limited, as the sector is likely to witness checks from poor healthcare infrastructure in the emerging markets. Also, strict laws imposed upon drug manufacturers would also act as a significant hindrance to the market’s growth. The leading participants from the obesity management market are GlaxoSmithKline plc., VIVUS, Inc., and F. Hoffmann La Roche Ltd.  


For more information on this report visit - http://www.futuremarketinsights.com/reports/obesity-management-market